

Scientific Program



apsa 
Australasian Pharmaceutical Science Association

APSA-ASCEPT

JOINT SCIENTIFIC MEETING 2015

Drugs to medicines: up close and personal

29 November - 2 December 2015
Hotel Grand Chancellor Hobart


ASCEPT

www.apsa-ascept2015.com

Saturday 28 November 2015

14:00 – 16:00	OSCE workshop
	Venue: University of Tasmania, Medical Sciences Precinct, Room 158/159, Level 1, 17 Liverpool St, Hobart
	Chair: Assoc Prof Parisa Aslani
	OSCEs and their role as an assessment tool , Dr Safeera Hussainy, Monash University
	The logistics of OSCEs , Prof Richard Hays, University of Tasmania
	Q&A / discussion time
	<ul style="list-style-type: none"> · break out groups (Science, Medicine and Pharmacy) · common (all courses) and specific questions (eg Science courses)
	Wrap-up
	Informal dinner: The Mill on Morrison, 11 Morrison Street, Hobart

Sunday 29 November 2015

09:30 – 19:30	Registration desk open Federation Foyer, Mezzanine Level		
10:00 – 13:00	ASCEPT Board meeting	10:00 – 11:40	
	Room: Harbour View Room 2	Pharmacogenomics workshop	
		Room: Grand Ballroom 2	
		Chair: Prof Andrew Somogyi	
		Pharmacogenetic studies in adults and children with cancer Prof Alan Boddy, University of Sydney	
		Implications and challenges of genome-wide association study in pharmacogenomics research Dr Siew-Kee Low, University of Sydney	
		Drug hypersensitivity Dr Ana Alfirevic, University of Liverpool, UK	
		11:40 – 12:00	
		Pharmacogenomics SIG AGM	
			12:30 – 15:30
			Education Forum
14:30 – 16:30	Careers workshop	Clinical Pharmacology workshop	Room: Grand Ballroom 3
	Room: Grand Ballroom 1	Room: Grand Ballroom 2	Chair: Dr Anna-Marie Babey
	Chairs: Ms Erica Diezmos; Ms Pamela Srouf	Chair: Assoc Prof Darren Roberts	12:30 – 14:00 Benchmarking Dr Sara Booth, The University of Tasmania
	Beyond tradition — where to next? Prof Andrew McLachlan, The University of Sydney; Concord Hospital Dr Annette Gross, GlaxoSmithKline Prof Martin Michel, Johannes Gutenberg University, Germany Dr Orin Chisholm, University of New South Wales Dr Bill Smith, Gilead Sciences, USA	Assessing evidence in drug safety Assoc Prof Darren Roberts, Medical School, Australian National University; Renal Medicine, The Canberra Hospital Dr Adam La Caze, School of Pharmacy, The University of Queensland	14:00 – 15:30 Blended learning ideas exchange workshop
		Sponsored by	
			15:30 – 16:30
			ASCEPT Education forum AGM
			Room: Grand Ballroom 3
16:30 – 16:55		16:30 – 16:55	
		ASCEPT Clinical Pharmacology AGM	
		Room: Grand Ballroom 2	
17:00 – 18:00	Conference opening and keynote address		
	Room: Concert Hall		
	Chair: Assoc Prof Peter Molenaar		
	Assoc Prof Parisa Aslani, President, APSA Assoc Prof Peter Molenaar, President, ASCEPT Prof Peter Rathjen, Vice-Chancellor, The University of Tasmania		
	And then there were three – lessons from a convoluted drug development project - 100 Prof Martin Michel, Johannes Gutenberg University, Germany		Sponsored by
			
18:00 – 19:30	Welcome reception		
	Hotel Grand Chancellor Hobart, Mezzanine Level		

Monday 30 November 2015

07:30 – 18:00	Registration desk open Federation Foyer, Mezzanine Level			
08:30 – 09:30	British Pharmacological Society keynote address			
	Room: Concert Hall			Sponsored by 
	Chair: Assoc Prof Peter Molenaar			
	Pharmacogenetics including personalisation of treatment in cardiovascular medicine through next generation sequencing - 101 Dr Ana Alfrevic, University of Liverpool, UK			
09:30 – 10:25	Morning tea with exhibitors Poster presentations: Cardiovascular, Clinical Pharmacology, Drug Discovery, Pharmacy Practice Federation Ballroom			
10:30 – 12:30	Symposium 1: Misuse of pharmaceuticals and herbal medications: Epidemiology and implications	Symposium 2: Discovery and development of novel anti-fibrotic therapies	Symposium 3: Pharmacokinetic challenges to drug development and clinical implementation Sponsored by 	Symposium 4: Recent advances and therapeutic developments in purinergic signalling
	Room: Grand Ballroom 1 Chairs: Dr Jenni Ilomäki; Dr Ian Musgrave	Room: Grand Ballroom 2 Chair: Assoc Prof Chrisan Samuel Assoc Prof Kevin Pflieger	Room: Grand Ballroom 3 Chairs: Dr Andrew Rowland; Dr David Foster	Room: Concert Hall Chair: Dr Lu Liu
10:30 – 11:00	Pharmaceutical drug misuse: Implications for post-market surveillance - 102 Prof Nicholas Buckley, The University of Sydney	Development of novel anti-fibrotic treatment for chronic kidney and heart disease - 106 Dr Yuan (Michael) Zhang, The University of Melbourne	The Pharmacokinetic intersection of academia, hospital and pharmaceutical industry - 110 Dr Vidya Perera, Bristol-Myers Squibb	Sensory innervation of the gut and bladder - role of purines - 114 Prof Simon Brookes, Flinders University
11:00 – 11:30	Opioid substitution therapy among prisoners: Longitudinal findings from a data linkage study - 103 Dr Natasa Gisev, University of New South Wales	Role of oxidative stress in the development of pulmonary fibrosis? - 107 Assoc Prof Ross Vlahos, RMIT University	Dose individualisation of sunitinib and tamoxifen - 111 Assoc Prof Howard Gurney, Westmead Hospital	Effect of infection and inflammation on purinergic signalling in the urinary bladder: A trigger for Detrusor Overactivity? - 115 Assoc Prof Kylie Mansfield, University of Wollongong
11:30 – 12:00	Misuse of herbal medicines: An emerging issue - 104 Dr Ian Musgrave, The University of Adelaide	Relaxin: A pleiotropic hormone with potent anti-fibrotic actions - 108 Assoc Prof Chrisan Samuel, Monash University	Across the continuum: DMPK experiences from preclinical to market - 112 Dr Bill Smith, Gilead Sciences Sponsored by 	P2X1-purinergic antagonists as potential male contraceptives - 116 Dr Sab Ventura, Monash University
12:00 – 12:30	Trends in pharmaceutical drug-related harms - 105 Assoc Prof Belinda Lloyd, Monash University	Insulin regulated aminopeptidase: A novel target to treat cardiac fibrosis - 109 Dr Tracey Gaspari, Monash University	Medicines regulation and pharmacokinetics: An academic perspective - 113 Prof Andrew McLachlan, The University of Sydney	Postjunctional GPCR regulation of lower urinary tract purinergic responses - 117 Prof Russ Chess-Williams, Bond University
12:30 – 13:25	Lunch with exhibitors Poster presentations: Cardiovascular, Clinical Pharmacology, Drug Discovery, Pharmacy Practice Federation Ballroom			12:30 – 13:00 Drug Disposition and Response SIG AGM Room: Grand Ballroom 3
				12:30 – 13:00 Respiratory & Inflammation SIG AGM Room: Concert Hall
				12:30 – 13:00 Toxicology SIG AGM Room: Grand Ballroom 1
				13:00 – 13:25 APSA Council Meeting Room: Grand Ballroom 2

Monday 30 November (cont'd)

13:30 – 15:30	Oral presentations 1: Pharmacy Practice	Oral presentations 2: Pharmacoepidemiology	Oral presentations 3: Cardiovascular	Oral presentations 4: Drug Discovery
	Room: Grand Ballroom 1	Room: Grand Ballroom 2	Room: Grand Ballroom 3	Room: Concert Hall
	Chair: Dr Leanne Chalmers	Chair: Dr Prasad Nishtala	Chair: Dr Tim Murphy	Chair: Assoc Prof Kevin Pflieger
13:30 – 13:45	Standardised over-the-counter medicine labels – can we do it? - 118 Ms Vivien Tong, The University of Sydney	Prioritising interventions to address polypharmacy in Australian aged care facilities - 126 Ms Kate Wang, Monash University	NOX2 oxidase promotes prostate tumour development - 134 Mr Ian Harrison, Monash University	Dimer interfaces are implicated in the structural basis of allosterism at metabotropic glutamate receptor 5 - 142 Dr Karen Gregory, Monash University
13:45 – 14:00	How do the stakeholders perceive the changing situation in Australian community pharmacy? - 119 Mr Andi Hermansyah, The University of Sydney	What's most important to residents and health care professionals when deprescribing in residential aged care facilities? - 127 Mr Justin Turner, Monash University	Des-acylated ghrelin limits brain injury and blood-brain barrier disruption after stroke - 135 Dr Alyson Miller, RMIT University	Enhanced glucose uptake in brite/beige adipocytes following adrenoceptor activation - 143 Dr Dana Hutchinson, Monash University
14:00 – 14:15	Unconscious implicit attitudes as a predictor of medicines adherence and self-medication - 120 Dr James Green, University of Otago	Older adults' and carers' beliefs and attitudes towards deprescribing - 128 Dr Emily Reeve, The University of Sydney	HNO donor isopropylamine NONOate offers haemodynamic advantages over the NO donor diethylamine NONOate in the diabetic rat myocardium ex vivo - 136 Mr Jarryd Anthonisz, Baker IDI Heart and Diabetes Research Institute	Identifying the orthosteric vestibule and an allosteric binding site of the α_{1A} adrenoceptor - 144 Dr Angela Finch, University of New South Wales
14:15 – 14:30	What do consumers want to know about drugs (medication and lifestyle) in their pregnancy journey? - 121 Dr Treasure McGuire, The University of Queensland; Mater Health Services Brisbane	Are polypharmacy and medication regimen complexity associated with all-cause mortality in older people? A population-based cohort study - 129 Ms Barbara Wimmer, Monash University	Loss of Alzheimer's-associated tau (MAPT) impairs cardiovascular function - 137 Mr Ashenafi Haileyesus Betrie, The University of Melbourne	Mechanisms of selectivity for allosteric modulators of the muscarinic acetylcholine receptors (mAChRs) - 145 Dr Celine Valant, Monash Institute of Pharmaceutical Sciences
14:30 – 14:45	Over-the-counter supply of combination analgesics containing codeine in community pharmacy: A simulated patient study - 122 Dr Joy Spark, La Trobe University	Statin discontinuation in older people with dementia: A pharmacoepidemiological study - 130 Ms Sujita Narayan, University of Otago	Phosphoinositide 3-kinase [p110α] (PI3K) gene therapy attenuates type 1 diabetic cardiomyopathy in mice - 138 Mr Darnel Prakoso, Baker IDI Heart and Diabetes Institute	Probing the pharmacology of the α_{1A}-adrenoceptor with fluorescent prazosin - 146 Miss Linzi Lim, Monash University
14:45 – 15:00	Consumer perceptions of service quality in Australian community pharmacies - 123 Mr Ardalan Mirzaei, The University of Sydney	Patterns in use and costs of disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs (bDMARDs) in Australia - 131 Miss Ellen Donges, The University of Queensland	The effects of Th2 cytokines to modulate macrophage phenotype and reactive oxygen species generation - 139 Ms Tara McConaghy, Monash University	Identification of the molecular determinants of adenosine A_1 receptor allosteric modulation - 147 Dr Lauren May, Monash University
15:00 – 15:15	Examining hospital pharmacists' goals for medication counselling within the communication accommodation theoretical framework - 124 Ms Bernadette Chevalier, The University of Queensland	A model for predicting high bleeding risk among potential warfarin users - 132 Miss Saranya Ramesh, Monash University	Chronic β1-blockade impairs ischaemic tolerance and preconditioning in murine myocardium - 140 Miss Louise See Hoe, Griffith University	Compartmentalised signalling of the Calcitonin Gene-Related Peptide (CGRP) Receptor - 148 Dr Meritxell Canals, Monash Institute of Pharmaceutical Sciences
15:15 – 15:30	Exploring the role of health beliefs in medication adherence in individuals with asthma - 125 Ms Holly Foot, The University of Queensland	Improving the assessment of drug safety: An analysis of the clopidogrel-proton pump inhibitor interaction - 133 Dr Adam La Caze, The University of Queensland	Deficiency of endogenous annexin-A1 exaggerates cardiomyopathy in a mouse model of type 1 diabetes - 141 Ms Sarah Rosli, Monash University; Baker IDI Heart and Diabetes Institute	Site-directed mutagenesis at the dopamine D_2 receptor reveals key residues involved in receptor activation and biased agonism - 149 Ms Carmen Klein Herenbrink, Monash University
15:30 – 15:55	Afternoon tea with exhibitors Federation Ballroom			Drug Discovery SIG AGM Room: Concert Hall
			15:40 – 15:55 Overcoming the challenge of analysing drugs, toxins and metabolites in real samples Dr Paul Wynne, Shimadzu Room: Grand Ballroom 1	Cardiovascular SIG AGM Room: Grand Ballroom 3
				Neuropharmacology SIG AGM Room: Grand Ballroom 2

Monday 30 November (cont'd)

16:00 – 18:00	Oral presentations 5: Pharmacy Practice	Oral presentations 6: Clinical Pharmacology	Oral presentations 7: Respiratory & Inflammation	Oral presentations 8: Pharmacoepidemiology /Toxicology
	Room: Grand Ballroom 1	Room: Grand Ballroom 2	Room: Grand Ballroom 3	Room: Concert Hall
	Chair: Assoc Prof Neil Cottrell	Chairs: Prof Sarah Hilmer; Dr Emily Reeve	Chairs: Assoc Prof Ross Vlahos; Dr Stavros Selemidis	Chair: Dr Ian Musgrave
16:00 – 16:15	“Use with caution in renal impairment” – implications for drug dosing in the general practice setting - 150 Ms Margaret Jordan, Bulli Medical Practice; Woonona Medical Practice	A mathematical model of the metabolic pathway for azathioprine and 6-mercaptopurine - 158 Prof Murray Barclay, Christchurch Hospital	NOX2 oxidase expressed in endosomes exacerbates viral pathogenicity - 166 Miss Eunice To, Monash University	An ecological study of the extent and factors associated with use of prescription and over-the-counter codeine in Australia - 174 Dr Natasa Gisev, University of New South Wales
16:15 – 16:30	Clinicians’ attitudes and perceptions regarding stroke prevention in atrial fibrillation - 151 Ms Bryony Scott, University of Tasmania	Impact of deprescribing of polypharmacy on adverse geriatric outcomes - 159 Prof Sarah Hilmer, Royal North Shore Hospital; The University of Sydney	Urokinase-dependent plasminogen activation mediates increased interleukin-6 in lung fibrogenesis - 167 Dr Michael Schuliga, The University of Melbourne	Spontaneously reported haemorrhagic adverse events associated with rivaroxaban in Australia - 175 Ms Esa Chen, Monash University
16:30 – 16:45	SMART-AF: Development of a decision support smartphone app to improve antithrombotic prescribing in atrial fibrillation - 152 Dr Leanne Chalmers, University of Tasmania	Medicine information exchange networks among health care professionals and prescribing in geriatric medicine wards - 160 Mr Bosco Chan, The University of Sydney	Airway smooth muscle conditioned media protects airway epithelial cells from the viral-induced glucocorticoid insensitivity - 168 Dr Yuxiu Connie Xia, The University of Melbourne	Association rule and frequent-set analysis: Potential adverse drug reactions (ADRS) pharmacovigilance method - 176 Prof David LeCouteur, The University of Sydney
16:45 – 17:00	Home Medicines Review following acute coronary syndromes: Preliminary results from a randomised controlled trial - 153 Mr Daniel Bernal, University of Tasmania	Pharmacokinetics and efficacy of oral frusemide in decompensated vs. compensated heart failure - 161 Dr Maneesha Dedigama, Flinders Medical Centre	Inhibition of NOX2 oxidase via a novel endosome specific inhibitor reduces influenza A virus (IAV)- induced lung inflammation - 169 Mr Raymond Luong, Monash University	Drug overdose in the elderly - 177 Dr Sivarajah Ilango, Princess Alexandra Hospital
17:00 – 17:15	Hospital readmission for major bleeding or thromboembolic complications in patients with atrial fibrillation - 154 Mrs Durga Bista, University of Tasmania	Prescribing of oral anticoagulants in older inpatients: Has the availability of newer agents led to inappropriate prescribing practices? - 162 Dr Nicholas Farinola, Royal Adelaide Hospital	Assessing changes in airway and vascular remodelling and contraction in a mouse model of bronchopulmonary dysplasia - 170 Mr Maurice Kroon, Monash University	Integration of multiple computational models of bioassays improve in vivo rodent carcinogenicity prediction - 178 Mr Davy Guan, Sydney University
17:15 – 17:30	Association of antihypertensive medication class and falls in the elderly: Systematic review and meta-analysis - 155 Mr Reza Kahladee, The University of Sydney	What Is Polypharmacy Exactly (WIPE) study - 163 Dr Gao Jing Ong, Queen Elizabeth Hospital	Serelaxin is an epithelial-dependent bronchodilator in rat precision cut lung slices and trachea - 171 Miss Maggie Lam, Monash University	NQO1-dependent Mito-Toxicity of Clioquinol - 179 Ms Jamuna Chhetri, University of Tasmania
17:30 – 17:45	National survey of community pharmacy’s capacity to screen for the risk of cardiovascular disease - 156 Prof Ines Krass, The University of Sydney	Drug-drug interaction alerts in an electronic prescribing system - 164 Dr Philip Drennan, Canterbury District Health Board	GPR40 and GPR120 – Novel targets for the treatment of lung disease - 172 Ms Chantal Donovan, Monash University	Ageing and drug induced liver injury: Insights from animal studies - 180 Mr John Mach, The University of Sydney; Royal North Shore Hospital
17:45 – 18:00	Understanding healthcare professionals’ perspectives on Nepalese patients’ diabetes management - 157 Ms Sujata Sapkota, The University of Sydney	What effect does methotrexate have on the liver in patients with a rheumatologic condition? - 165 Dr Andrew Finch, Royal Brisbane Hospital	Regulation of PAR₂ trafficking and resensitization by Gβγ and PKD - 173 Dr Peishen Zhao, Monash University	Optimising the logistics of life-saving drug procurement and supply in NSW and the ACT - 181 Dr Alexandra Bennett, NSW Therapeutic Advisory Group

Therapeutic Guidelines

Independent Reliable Relevant Respected

For more information
visit www.tg.org.au

Therapeutic
Guidelines

Tuesday 1 December 2015

08:00 – 17:00	Registration desk open Federation Foyer, Mezzanine Level			
07:45 – 08:20	APSA AGM Room: Grand Ballroom 1			
08:30 – 09:30	APSA Medal Oration Room: Concert Hall Chair: Assoc Prof Parisa Aslani Innovation, quality, translation: Across the borders - 200 Prof Sanjay Garg, University of South Australia			
09:30 – 10:25	Morning tea with exhibitors Poster presentations: Education, Drug Disposition and Response, Respiratory & Inflammation, Neuro- and Behavioural Pharmacology, Pharmaceutical Science, Pharmacy Education, Pharmacoepidemiology, Pharmacogenomics, Toxicology, Urogenital and Gastrointestinal Federation Ballroom			Sponsored by 
10:30 – 12:30	Symposium 5: Influence of kidney function on drug disposition and response Room: Grand Ballroom 1 Chair: Prof Ric Day	Symposium 6: Novel approaches for delivery of biologics Room: Grand Ballroom 2 Chair: Dr Joe Nicolazzo	Symposium 7: Preparing graduates for the workplace Room: Grand Ballroom 3 Chair: Assoc Prof Elizabeth Davis	Symposium 8: Ethnicity and personalised medicine Room: Concert Hall Chairs: Dr John Duley; Dr Ana Alfirevic
10:30 – 11:00	Overview of changes in drug disposition with impaired kidney function - 201 Assoc Prof Darren Roberts, Australian National University Medical School; The Canberra Hospital	Improving the lung exposure of therapeutic proteins following inhaled delivery via optimal PEGylation - 205 Dr Lisa Kaminskas, Monash University	What outcomes do we want for our graduates? - 209 Prof Brian Yates, The University of Tasmania	Ethnopharmacology: From drugs to medicines for all populations - 213 Dr Annette Gross, GlaxoSmithKline
11:00 – 11:30	Optimising drug dosing in acute kidney injury and renal replacement therapies - 202 Prof Jason Roberts, The University of Queensland	Formulation of DNA for intramuscular administration - 206 Prof Colin Pouton, Monash University	Translating research experiences to employability skills: Using evidence to make a convincing case - 210 Dr Kirsten Zimbardi, The University of Queensland	CYP2C19 genetics in Maori and Pacific peoples - 214 Assoc Prof Nuala Helsby, University of Auckland
11:30 – 12:00	Novel imaging techniques for assessing renal disposition in vivo - 203 Dr Xin Liu, The University of Queensland	Exploiting mucosal surfaces for delivery of antigens - 207 Prof Michael Roberts, University of South Australia; The University of Queensland	Developing career ready graduates - 211 Dr Laurence Orlando, Monash University	Personalised medicines for Aboriginal Australians - 215 Prof Andrew Somogyi, University of Adelaide
12:00 – 12:30	Augmented renal clearance: Effects on drug disposition and clinical response - 204 Assoc Prof Andrew Udy, Alfred Hospital; Monash University	Delivery platforms for maximising immunisation responses - 208 Prof Sarah Hook, University of Otago	Preparedness for prescribing: What do your medical students think - 212 Ms Claire Johnston, Australian National University	Interethnic differences in pain, analgesia and neuroimmunogenetics - 216 Dr Daniel Barratt, University of Adelaide
12:30 – 13:25	Lunch with exhibitors Poster presentations: Education, Drug Disposition and Response, Respiratory & Inflammation, Neuro- and Behavioural Pharmacology, Pharmaceutical Science, Pharmacy Education, Pharmacoepidemiology, Pharmacogenomics, Toxicology, Urogenital and Gastrointestinal Federation Ballroom			12:30 – 13:00 Pharmacoepidemiology SIG AGM Room: Concert Hall



STUDY WITH THE BEST



Research and Training


- ♦ Research laboratories housed state-of-the-art buildings
- ♦ International and award-winning faculty including Nobel Laureate Adjunct Professor Brian Kobilka
- ♦ Core facilities offering cutting-edge services:
 - ♦ Whole-animal Imaging Core, Murine Disease Model Facility, Radioisotopic, Assay Core, FACS Core
 - ♦ Cell Signaling Core, Ex vivo pharmacology, Mammalian Cell Culture, Molecular Modelling, Molecular Biology Core
- ♦ Range of therapeutic foci: Cancer, Metabolic Disease, CNS Disorders, Inflammation and Pain and Cardiovascular Disease
- ♦ Generous scholarships are available to support outstanding PhD prospects



Cellular
Screening, Signal profiling
Analytical pharmacology

Cellular
Microscopic imaging
High content imaging

In Vivo
Behavioural testing
Small animal imaging



Molecular
Structural biology &
Molecular modelling

Cellular
Protein-protein
interactions

Tissue physiology
Langendorf heart
Brain slices

**WE ARE SOCIAL!
FIND US ON!**



Tuesday 1 December (cont'd)

13:30 – 15:30	Oral presentations 9: ASCEPT Garth McQueen Oral Prize	Oral presentations 10: Pharmacy Practice	Oral presentations 11: Clinical Pharmacology	Oral presentations 12: Pharmaceutical Science
	Room: Grand Ballroom 1	Room: Grand Ballroom 2	Room: Grand Ballroom 3	Room: Concert Hall
	Chair: Dr Nicole Jones	Chair: Assoc Prof Rhiannon Braund	Chair: Assoc Prof Matt Doogue	Chair: Dr Lisa Kaminskas
13:30 – 13:45	Pharmacological Inhibition of Insulin Regulated Aminopeptidase (IRAP) completely reverses age-mediated Cardiac Fibrosis - 217 Miss Huey Wen Lee, Monash University	Factors influencing patients' adherence to antidepressant medicines in unipolar depression: A qualitative study - 224 Miss Pornchanok Srimongkon, The University of Sydney	Personalising busulfan in children; from assessment of new dose regimens to individualised limited sampling for therapeutic drug monitoring - 232 Dr Sam Salman, University of Western Australia	Styrene maleic acid micelles as a nanocarrier system for oral delivery of paclitaxel - 240 Ms Neha Parayath, University of Otago
13:45 – 14:00	Implementation of the Drug Burden Index with Home Medicines Review in older Australians: A feasibility and utility study - 218 Ms Lisa Kouladjian, The University of Sydney	Spontaneous adverse event reports associated with zolpidem - 225 Ms Carmen Wong, The University of Sydney	Systemic inflammation predicts drug pharmacokinetics and clinical outcomes in advanced non-small cell lung cancer patients receiving paclitaxel and carboplatin chemotherapy - 233 Mr Benjamin Harris, The University of Sydney	Development of a physically stable high dose powder for inhalation by spray-drying - 241 Dr Shyamal Das, University of Otago
14:00 – 14:15	Digoxin withdrawal in stable heart failure with reduced ejection fraction in sinus rhythm - A randomised controlled trial - 219 Dr Ingrid Hopper, Monash University	Exploring the visible components of organisational culture: What influences the use of psychotropic medicines in nursing homes? - 226 Miss Mouna Sawan, Sydney University	Utility of the OncoFOCUS™ +KIT somatic cancer mutation screen in directing targeted pharmacotherapy - 234 Dr Thomas Polasek, Flinders University	Development of localized stent drug delivery system for esophageal cancer - 242 Prof Sanjay Garg, University of South Australia
14:15 – 14:30	Assessment of the potential remodelling of calcium signalling in human breast cancer-associated fibroblasts - 220 Ms Teneale Stewart, The University of Queensland	Targeting health related quality of life (HRQoL) in pharmaceutical care: A systematic review and meta-analysis of the impact of pharmaceutical care services on quality of life - 227 Mr Mohammed Mohammed, The University of Sydney	Cerebrospinal fluid pharmacokinetics of tobramycin following intraventricular administration - 235 Ms Pamela Buffery, Canterbury District Health Board	Enhancing topical delivery of glutathione by utilizing chemical modification and niosomal delivery systems - 243 Mr Murad Al-Gailani, University of Auckland
14:30 – 14:45	Understanding the mechanism of action of a novel class of allosteric modulator of the dopamine D₂ receptor - 221 Mr Christopher Draper-Joyce, Monash University	Potential medicine sharing risk reduction strategies: A qualitative analysis of patients' and health professionals' views using the Behaviour Change Wheel - 228 Mr Kebede Beyene, University of Auckland	Flucloxacillin: Total concentrations poorly reflect unbound concentrations in hospitalised patients - 236 Dr Paul Chin, Christchurch Hospital; University of Otago	Characterization of Gloop: Is it suitable for medication delivery in dysphagic patients? - 244 Dr Juliana Manrique, The University of Queensland
14:45 – 15:00	Paracetamol hepatotoxicity in mice: Effect of age, frailty, N-acetyl cysteine and exposure type - 222 Ms Alice Kane, Kolling Institute	Sedatives and safety: A matter of risk perception and communication between pharmacists and patients - 229 Mr Ibrahim Jomaa, The University of Sydney	Antibiotics prescribed to patients receiving haemodialysis in both the community and hospital settings - 237 Ms Katrina Hui, Monash University	Solubility and stability improvement of Curcumin using solid dispersion approach - 245 Mr Ankitkumar Parikh, University of South Australia
15:00 – 15:15	New horizons for male contraception: A non-hormonal approach via blockade of P2X1-purinoreceptors and α_{1A}-adrenoceptors - 223 Ms Nicole Eise, Monash University	Does mental health first aid training affect MPharm students' literacy, knowledge and attitudes towards perinatal depression? A pre-test/post-test pilot study - 230 Ms Sarira El-Den, The University of Sydney	Febuxostat: An analysis of its dose-response relationship with serum urate - 238 Mr Diluk Kannangara, University of New South Wales; St Vincent's Hospital	A semi-physiologically based pharmacokinetic model and a time-to-event model to explore leflunomide disposition and cessation due to toxicity - 246 Mr Ashley Hopkins, University of South Australia
15:15 – 15:30		The role of medicinal cannabis in clinical therapy - Pharmacists' perspectives - 231 Mr Sami Isaac, The University of Sydney	Metformin and weight loss: An exposure-response relationship - 239 Mr Shaun Kumar, St Vincent's Hospital	Towards point of care analysis of ampicillin from whole blood - 247 Dr Rosanne Guijt, University of Tasmania

Tuesday 1 December (cont'd)

15:30 – 15:55	Afternoon tea with exhibitors Federation Ballroom
16:00 – 17:00	ASCEPT Michael Rand Medal lecture Room: Concert Hall Chair: Assoc Prof Peter Molenaar The Greenfields of Geriatric Pharmacology Prof David LeCouteur, Centre for Education & Research on Ageing, The University of Sydney
17:00 – 18:00	ASCEPT AGM Room: Concert Hall
19:00 – 23:00	Meeting dinner Hobart Function and Conference Centre, 1 Elizabeth Street Pier, Hobart



QIMR Berghofer
Medical Research Institute

Translational Research Excellence

21 October 2015 | Brisbane, Australia.

Translational Research: an Overnight Success
...10 years in the making

Exploring the journey of therapeutic product development

Visit www.trx16.com.au for information

Life Sciences Queensland

CENTRE FOR EDUCATION & RESEARCH ON AGEING

About CERA

www.cera.edu.au

The Centre for Education and Research on Ageing (CERA) aims to expand and share knowledge of human ageing, so that the health and quality of life of older people can be improved.

CERA is a joint facility of the University of Sydney, Sydney Medical School and Concord Repatriation General Hospital, a teaching hospital within the Sydney Local Health District. CERA is located at Concord Repatriation General Hospital in the inner west of Sydney, Australia.

CERA's Research Programs

Research at CERA is concerned with the ageing process, and the disorders and diseases that are most likely to cause disability and reduced quality of life in old age. Our Research Program is multidisciplinary, linking laboratory, clinical, epidemiological and health services research. Allied to this are educational programs at basic and advanced level of practice in Geriatric Medicine, also other educational programs for aged care workers from a range of professional settings.

SUPPORTED BY: AGEING AND ALZHEIMERS INSTITUTE

Contact: cera@cera.edu.au or (02) 9767 7212



Wednesday 2 December 2015

08:00 – 16:30	Registration desk open Federation Foyer, Mezzanine Level			
08:30 – 09:30	Japanese Pharmacological Society keynote address			
	Room: Concert Hall			
	Chair: Prof Dominic Geraghty			
	Transporters in pharmacology and molecular target drug discovery - 300 Prof Yoshikatsu Kanai, Osaka University, Graduate School of Medicine, Japan			
09:30 – 10:25	Morning tea			
	Poster presentations: Pharmacy Practice			
	Federation Ballroom			
10:30 – 12:30	Symposium 9: An up-close look at novel targets for breast cancer	Symposium 10: Adverse drug reactions, is electronic prescribing a panacea?	Symposium 11: Novel approaches to drug safety: Beyond randomised controlled trials	Symposium 12: Denis Wade Johnson & Johnson New Investigators
	Room: Grand Ballroom 1	Room: Grand Ballroom 2	Room: Grand Ballroom 3	Room: Concert Hall
	Chair: Dr Angela Finch	Chair: Assoc Prof Darren Roberts	Chair: Dr Jenni Ilomäki	Chair: Prof Dominic Geraghty
10:30 – 11:00	Morphine modulates breast cancer metastatic potential - 301 Assoc Prof Marie-Odile Parat, The University of Queensland	The burden of adverse drug events in older people - 305 Assoc Prof Simon Bell, Monash University	Balancing safety and quality of life. Listening to what consumers want. - 309 Ms Tara Quirke, Consumer Dementia Research Network, Alzheimer's Australia	A small-molecule formyl peptide receptor (FPR) agonist limits myocardial reperfusion injury <i>in vivo</i>: Unmasking ligand-biased agonism as a novel cardioprotective mechanism - 313 Dr Chengxue Qin, Baker IDI Heart & Diabetes Institute
11:00 – 11:30	Inflammation resolution mediators in breast cancer - 302 Prof Alastair Stewart, University of Melbourne	The misdiagnosis of ADRs - 306 Assoc Prof Matt Doogue, Otago University	Genetic screening for people at risk of adverse drug events: Costs vs benefits from the individual and societal perspective - 310 Prof Danny Liew, The University of Melbourne	Adrenoceptors promote glucose uptake into adipocytes and muscle by an insulin-independent signalling pathway involving mTORC2 - 314 Dr Masaaki Sato, Monash University
11:30 – 12:00	UDP-glucuronosyltransferases (UGTs) and steroid hormone regulation in breast cancer - 303 Dr Robyn Meech, Flinders University	Adverse drug events: The cost-effectiveness of moving from paper to electronic systems - 307 Prof Johanna Westbrook, Australian Institute of Health Innovation, Macquarie University	Non-experimental evaluation of medical products: Challenges and established approaches - 311 Assoc Prof Alan Brookhart, University of North Carolina	Understanding biased signalling and allosteric modulation at the glucagon-like peptide-1 receptor - 315 Dr Denise Wootten, Monash University
12:00 – 12:30	Development of a novel class of ω-3-fatty acid epoxide analogues with <i>in vivo</i> activity against breast cancer - 304 Prof Michael Murray, The University of Sydney	eSystems decision support, a panacea for ADRs? - 308 Dr Sepehr Shakib, Royal Adelaide Hospital	Register-based pharmacoepidemiology – Insights from research using the Nordic prescription databases - 312 Dr Jenni Ilomäki, Monash University	Essential roles of the store-operated calcium channel ORAI1 in the mammary gland - 316 Dr Felicity Davis, The University of Queensland; University of Cambridge
12:30 – 13:25	Lunch Student poster finalists presentations			
	Federation Ballroom			12:55 – 13:25 Urogenital & Gastrointestinal SIG AGM
				Room: Grand Ballroom 1



SHIMADZU
Excellence in Science

discovery to confirmation | we're with you

AUS: 1800 800 950
NZ: 0800 127 446
info@shimadzu.com.au
shimadzu.com.au

CHROMATOGRAPHY | LIFE SCIENCE | SPECTROSCOPY | ANALYSERS | BALANCES | MATERIALS TESTING

Wednesday 2 December (cont'd)

13:30 – 15:00	Oral presentations 13: Urogenital & Gastrointestinal/ Neuro- & Behavioural Pharmacology	Oral presentations 14: Drug Disposition and Response	Oral presentations 15: Drug Discovery/ Pharmaceutical Science	Oral presentations 16: Education
	Room: Grand Ballroom 1	Room: Grand Ballroom 2	Room: Grand Ballroom 3	Room: Concert Hall
	Chair: Dr Betty Exintaris	Chairs: Dr Andrew Rowland; Dr David Foster	Chairs: Dr Andrew Crowe; Dr Felicity Davis	Chair: Assoc Prof Lynette Fernandes
13:30 – 13:45	Calcium sensing receptor dysregulation in induced pluripotent stem cell derived podocytes from patients with Alport Syndrome - 317 Dr John Haynes, Monash University	Optimal time course of antibiotic concentrations in combination dosage regimens is critical to combat difficult-to-treat 'superbugs' - 323 Dr Cornelia Landersdorfer, Monash University	Inhibition of ocular neovascularization by gene delivery of calreticulin-derived peptide, vasostatin - 330 Dr Guei-Sheung Liu, Centre for Eye Research Australia	A flipped-classroom blended approach to the teaching of pharmacology - 336 Prof Emilio Badoer, RMIT University
13:45 – 14:00	The 5-HT₃ receptor C subunit modulates receptor function - 318 Assoc Prof Helen Irving, Monash University	Investigation of salbutamol enantiomer deposition in epithelial lining fluid in horses - 325 Dr Glenn Jacobson, University of Tasmania	Novel naphthoquinones against mitochondrial dysfunction-induced seizures - 331 Ms Monila Nadikudi, University of Tasmania	Increasing pharmacists' capabilities to integrate into health care teams through successful interprofessional communication - 337 Dr Karen Luetsch, The University of Queensland
14:00 – 14:15	The involvement of pannexin-1 channels and purinergic P2X7 receptors in cytokine-induced colitis in human colonic mucosa - 319 Miss Erica Diezmos, University of New South Wales	A physiologically based pharmacokinetic model for long-circulating nanoparticles - 326 Dr Xiaowen Liang, The University of Queensland	Preclinical pharmacological evaluation of CDKI-73 for treatment of acute myeloid leukaemia - 332 Ms Longjin Zhong, The University of South Australia	Development of a practical class for third year neuropharmacology students using zebrafish to demonstrate the actions of antiseizure drugs - 338 Dr Nicole Jones, University of New South Wales
14:15 – 14:30	Distinct effects of Zolpidem and Dual Orexin Receptor Antagonists in rats sleep-wake profile and EEG power spectrum - 320 Prof Daniel Hoyer, The University of Melbourne	A physiologically based kinetic model for elucidating the <i>in vivo</i> fate of mesenchymal stem cells - 327 Dr Haolu Wang, The University of Queensland	The involvement of fatty acid-binding protein 5 in the blood-brain barrier transport of docosahexaenoic acid and cognitive function - 333 Mr Yijun Pan, Monash University	Pharmacy Simulator: A 3D computer-based virtual patient simulator for training community pharmacists - 339 Dr Ivan Bindoff, University of Tasmania
14:30 – 14:45	Does chronic morphine treatment alter endogenous opioid function in the amygdala? - 321 Miss Gabrielle Gregoriou, The University of Sydney	Drug and chemical glucosidation by untransfected Supersomes™ (u-SUP) and microsomes from <i>Spodoptera frugiperda</i> 9 (Sf9) cells - 328 Ms Nuy Chau, Flinders University	Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy - 334 Prof Sanjay Garg, University of South Australia	A collaborative approach to embedding cultural competence into the Bachelor of Pharmacy curriculum - 340 Ms Sandra Holmes, University of Tasmania
14:45 – 15:00	Receptor dwell time determines bias towards internalisation of the μ opioid receptor - 322 Mr Alexander Gillis, The University of Sydney	Exemestane and its active metabolite 17-hydroexemestane up-regulate UDP-glucuronosyltransferase (UGT) 2B17 in breast cancer cells - 329 Miss Apichaya Chanawong, Flinders University	Amber teething necklaces: Is there any basis to their use in teething infants? - 335 Dr Esther Lau, Queensland University of Technology	Creating effective multimedia learning resources for the teaching of pharmacology - 341 Ms Chau Khuong, Monash University
15:00 – 15:15	Short comfort break			
15:15 – 16:15	APSA lecture			
	Room: Concert Hall			
	Chair: Assoc Prof Luke Bereznicki			
	Academic life in the spotlight: Maximizing productivity and fulfillment - 342 Prof Shane Desselle, Touro University California, USA			
16:15 – 16:45	Awards and close			
	Room: Concert Hall			

Thank you to our sponsors:

Platinum sponsor



Major sponsors



Key meeting sponsors



Life Sciences Queensland



Supporter



Exhibitors





Study Postgraduate Pharmacy



Take on the roles of the future.

By studying postgraduate Pharmacy online you'll develop your clinical knowledge and research skills, preparing you for the future.

Special offer

Study without tuition fees for all units completed in 2016*.

Applications close soon

utas.edu.au/postgrad-health



*conditions apply CRICOS Provider Code: 00586B